Reduced circulating apelin in essential hypertension and its association with cardiac dysfunction

被引:94
作者
Przewlocka-Kosmala, Monika [1 ]
Kotwica, Tomasz [1 ]
Mysiak, Andrzej [1 ]
Kosmala, Wojciech [1 ]
机构
[1] Med Univ, Dept Cardiol, Wroclaw, Poland
关键词
apelin; cardiac dysfunction; hypertension; ORPHAN RECEPTOR APJ; PEPTIDE APELIN; BLOOD-PRESSURE; IN-VIVO; LIGAND; ECHOCARDIOGRAPHY; CONTRACTILITY; COMMITTEE; INSULIN; SYSTEM;
D O I
10.1097/HJH.0b013e328344da76
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Objective Apelin - a novel multifunction peptide implicated in regulation of the cardiovascular system, including blood pressure and cardiac function control - has been postulated to be involved in the pathophysiology of hypertension and hypertensive heart disease. We investigated the circulating apelin level and its relationship to left ventricular function in patients with essential hypertension. Methods We enrolled 232 hypertensive patients without concomitant diseases affecting cardiovascular functions and 76 healthy controls. Each patient underwent plasma apelin measurement and echocardiographic assessment of left ventricular systolic and diastolic function using myocardial velocities and deformation parameters, and myocardial reflectivity using calibrated integrated backscatter. Results Hypertensive patients demonstrated lower plasma apelin than the controls (265 +/- 127 vs. 330 +/- 159 pg/ml; P<0.001). Patients with the lowest plasma apelin, that is, from the first tertile, exhibited more severe left ventricular systolic and diastolic function abnormalities than their peers from the other two tertiles. In multivariable regression analysis, apelin was, in addition to patient age, BMI, blood pressure, left ventricular mass index and calibrated integrated backscatter in the basal septum, an independent correlate of left ventricular systolic function parameters (beta=0.18; P<0.001 for strain and beta-0.12; P<0.03 for systolic strain rate) and diastolic function parameters (beta=0.13; P<0.01 for early diastolic strain rate, beta=0.11; P<0.04 for early diastolic myocardial velocity, and beta=-0.11; P<0.04 for the ratio of mitral inflow to mitral annular early diastolic velocity). Conclusion In patients with essential hypertension, circulating apelin levels are reduced, and lower plasma apelin is independently associated with more profound left ventricular systolic and diastolic function impairment. J Hypertens 29: 971-979 (C) 2011 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
引用
收藏
页码:971 / 979
页数:9
相关论文
共 34 条
[1]   Pulmonary apelin levels and effects in rats with hypoxic pulmonary hypertension [J].
Andersen, C. U. ;
Markvardsen, L. H. ;
Hilberg, O. ;
Simonsen, U. .
RESPIRATORY MEDICINE, 2009, 103 (11) :1663-1671
[2]   The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo [J].
Ashley, EA ;
Powers, J ;
Chen, M ;
Kundu, R ;
Finsterbach, T ;
Caffarelli, A ;
Deng, A ;
Eichhorn, J ;
Mahajan, R ;
Agrawal, R ;
Greve, J ;
Robbins, R ;
Patterson, AJ ;
Bernstein, D ;
Quertermous, T .
CARDIOVASCULAR RESEARCH, 2005, 65 (01) :73-82
[3]   Apelin has in vivo inotropic effects on normal and failing hearts [J].
Berry, MF ;
Pirolli, TJ ;
Jayasankar, V ;
Burdick, J ;
Morine, KJ ;
Gardner, TJ ;
Woo, YJ .
CIRCULATION, 2004, 110 (11) :II187-II193
[4]   Apelin, a newly identified adipokine up-regulated by insulin and obesity [J].
Boucher, J ;
Masri, B ;
Daviaud, D ;
Gesta, S ;
Guigné, C ;
Mazzucotelli, A ;
Castan-Laurell, I ;
Tack, I ;
Knibiehler, B ;
Carpéné, C ;
Audigier, Y ;
Saulnier-Blache, JS ;
Valet, P .
ENDOCRINOLOGY, 2005, 146 (04) :1764-1771
[5]  
Charles Christopher J., 2007, Cardiovascular & Hematological Agents in Medicinal Chemistry, V5, P1
[6]   Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction [J].
Chen, MM ;
Ashley, EA ;
Deng, DXF ;
Tsalenko, A ;
Deng, A ;
Tabibiazar, R ;
Ben-Dor, A ;
Fenster, B ;
Yang, E ;
King, JY ;
Fowler, M ;
Robbins, R ;
Johnson, FL ;
Bruhn, L ;
McDonagh, T ;
Dargie, H ;
Yakhini, Z ;
Tsao, PS ;
Quertermous, T .
CIRCULATION, 2003, 108 (12) :1432-1439
[7]  
CHOBANIAN AV, 2003, JAMA-J AM MED ASSOC, V289, P2560, DOI DOI 10.1161/01.HYP.0000107251.49515.C2
[8]   Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure [J].
Chong, KS ;
Gardner, RS ;
Morton, JJ ;
Ashley, EA ;
McDonagh, TA .
EUROPEAN JOURNAL OF HEART FAILURE, 2006, 8 (04) :355-360
[9]   Apelin increases contractility in failing cardiac muscle [J].
Dai, Tieying ;
Ramirez-Correa, Genaro ;
Gao, Wei Dong .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2006, 553 (1-3) :222-228
[10]   ECHOCARDIOGRAPHIC ASSESSMENT OF LEFT-VENTRICULAR HYPERTROPHY - COMPARISON TO NECROPSY FINDINGS [J].
DEVEREUX, RB ;
ALONSO, DR ;
LUTAS, EM ;
GOTTLIEB, GJ ;
CAMPO, E ;
SACHS, I ;
REICHEK, N .
AMERICAN JOURNAL OF CARDIOLOGY, 1986, 57 (06) :450-458